Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

Basit Öğe Kaydı
dc.authorid0000-0002-0077-6971
dc.authorid0000-0001-9584-0827
dc.authorid0000-0003-2715-4002
dc.authorid0000-0002-5823-1704
dc.authorid0000-0002-0443-6966
dc.authorid0000-0001-7934-7039
dc.authorid0000-0003-2342-073X
dc.contributor.authorGöktaş Aydın, Sabin
dc.contributor.authorKutlu, Yasin
dc.contributor.authorMuğlu, Harun
dc.contributor.authorAydın, Ahmet
dc.contributor.authorAçıkgöz, Özgür
dc.contributor.authorHamdard, Jamshid
dc.contributor.authorKarcı, Ebru
dc.contributor.authorBilici, Ahmet
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorYıldız, Özcan
dc.date.accessioned2024-02-23T09:10:45Z
dc.date.available2024-02-23T09:10:45Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground: Prostate cancer is a prevalent cancer in men worldwide, and castration-resistant prostate cancer (CRPC) is characterized by disease progression despite androgen deprivation therapy. While clinical and prognostic biomarkers have been identified in CRPC, the significance of serum inflammatory markers remains unclear. Materials and methods: This retrospective study included 79 CRPC patients treated with abiraterone or enzalutamide. Inflammatory markers, including the modified Glasgow prognostic score (mGPS), systemic immune-inflammation index (SII), and neutrophil-to-lymphocyte ratio (NLR), were assessed as predictive tools for treatment response. Patient data were obtained from medical charts, and statistical analyses were performed. Results: The median age of the patients was 67 years, with most having a Gleason score of 8–10. The median values for NLR, PLR, and SII were 2.9, 168.5, and 713.5, respectively. The objective response rate (ORR) to abiraterone or enzalutamide therapy was 55.1%. mGPS showed a significant association with ORR, with the mGPS 0 group having the highest response rate (59.5%). Median progression-free survival (PFS) was 12.8 months, and median overall survival (OS) was 35.4 months. Palliative radiotherapy during therapy and PSA doubling time were independent prognostic factors for PFS. Conclusions: mGPS and PSA doubling time significantly impacted survival, and mGPS significantly predicted the treatment response in mCRPC, which may lead to further prospective studies.
dc.identifier.citationGöktaş Aydın, S., Kutlu, Y., Muğlu, H., Aydın, A., Açıkgöz, Ö., Hamdard, J. ... Yıldız, Ö. (2024). Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Cancer Chemotherapy and Pharmacology, 93(1), 71-78. https://dx.doi.org/10.1007/s00280-023-04592-x
dc.identifier.doi10.1007/s00280-023-04592-x
dc.identifier.endpage78
dc.identifier.issn0344-5704
dc.identifier.issn1432-0843
dc.identifier.issue1
dc.identifier.pmid37773537
dc.identifier.scopus2-s2.0-85173018712
dc.identifier.scopusqualityQ1
dc.identifier.startpage71
dc.identifier.urihttps://dx.doi.org/10.1007/s00280-023-04592-x
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12308
dc.identifier.volume93
dc.identifier.wos001143741300007en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorGöktaş Aydın, Sabin
dc.institutionauthorKutlu, Yasin
dc.institutionauthorMuğlu, Harun
dc.institutionauthorAydın, Ahmet
dc.institutionauthorAçıkgöz, Özgür
dc.institutionauthorHamdard, Jamshid
dc.institutionauthorKarcı, Ebru
dc.institutionauthorBilici, Ahmet
dc.institutionauthorÖlmez, Ömer Fatih
dc.institutionauthorYıldız, Özcan
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectAbiraterone
dc.subjectCastration-Resistant Prostate Cancer
dc.subjectEnzalutamide
dc.subjectmGPS
dc.subjectObjective Response Rate
dc.subjectPSA Doubling Time
dc.titlePredictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Aydin-Sabin-2024.pdf
Boyut:
904.56 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu